Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis, and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients. At present, Philogen has four promising anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies are in planning. Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.

Embolx is a venture-backed start-up in Silicon Valley that is developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).

AI Metrics LLC develops imaging software to the radiology market. It creates transformational software that positions radiologists to be the most efficient, valuable clinicians in patient care. The company was founded by Andrew Smith and is headquartered in Birmingham, AL.

Researches and develops a small number of ethical pharmaceutical and medical products

Biocompatibles UK Ltd. is a company headquartered in Farnham, UK, that manufactures, and markets implantable products for patients. The firm was founded in 2001.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Guizhou Provincial People's Hospital is a private company headquartered in Guiyang, China, that provides medical services.

Daiwa Pharmaceutical manufactures, sells, and imports pharmaceuticals, quasi-drugs, and medical equipment.

Toshiba Corporation (株式会社東芝 Kabushiki-gaisha Tōshiba, English: /təˈʃiːbə, tɒ-, toʊ-/) is a Japanese multinational conglomerate headquartered in Tokyo, Japan. Its diversified products and services include information technology and communications equipment and systems, electronic components and materials, power systems, industrial and social infrastructure systems, consumer electronics, home appliances, medical equipment, office equipment, as well as lighting and logistics.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Hunan Xinshen Zhilin Chinese Herbal Pieces Co., Ltd., established on 2012-11-28, The business scope includes the processing of Chinese herbal decoction pieces;Planting of Chinese Herbal Medicine;Chinese herbal medicine processing,buy,Sales;Primary processing of agricultural products;Chinese Herbal Medicine,agricultural products,Pre-packaged food,Sales of bulk food;sales of tea,pack,to plant;Internet sales of agricultural products;Agricultural product acquisition;Production of Chinese herbal extracts;Traditional Chinese Medicine Hospital;Chinese Medicine;TCM Dermatology;Tea drinks and other beverages,Meter,Manufacturing of pasta;grain milling.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Develops, researches, and commercializes biopharmaceutical products for the treatment of hepatitis B, C, and solid tumors

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Guangzhou Mosheng Medical Technology Development Co., Ltd., established on 2021-04-27, The business scope includes the manufacture of teaching models and teaching aids;Sales of teaching models and teaching aids;Teaching equipment sales;Medical Research and Experimental Development;Sales of Class I Medical Devices;Medical equipment rental;software development;software sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;electronics sales;Office Equipment Sales;Network Equipment Sales;Information security equipment sales;Sales of mobile terminal equipment;Wholesale of computer software, hardware and auxiliary equipment;Broadcasting, film and television equipment sales;furniture sales;Home Appliance Sales;Household Goods Sales;Refrigeration,Air Conditioning Equipment Sales;Sales of plastic products;Metal Products Sales;Sales of building materials;Sales of building decoration materials;marketing planning;Educational Consulting Services(Education and training activities that do not include licensing approval);Information Consulting Service(Not including licensing information consulting services);Conference and Exhibition Services;Business Management Consulting;Data processing and storage support services;Information system integration service;Information Technology Consulting Services;;

Nobelpharma was founded in 2003, and in 2008 we obtained our first marketing approval for an ethical drug, NOBELZIN®. We now have marketing approvals for and sell 18 new drugs and one new medical device. In the pharmaceuticals industry, there are no companies of similar scale and age launching as many new drugs as we have. It is the pursuit of our unique product planning and research and development that has led to this achievement. We engage in the projects of "drugs and medical devices for unmet medical needs" which are critical but neglected. We chose not to carry out the time-consuming and costly basic researches. Instead, we conduct license negotiations and research activities focusing on patient needs and select the best possible candidates (new drug candidates) from outside our company. This is because we want to deliver the drugs and medical devices for unmet medical needs to the medical front as quickly as possible, for the benefit of the patients. Unique management strategy for

Bozhon Precision Industry Technology Co., Ltd. engages in the research, development, design, production, sales and technical services of automation equipment, automated flexible production lines, automation key components and tooling fixtures. It also provides overall solutions for smart factories. The company was founded by Lan Fang Chen and Xin E Lv on September 22, 2006 and is headquartered in Suzhou, China.